A Study of Sacituzumab Govitecan in People With Mesothelioma

Summary

Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.

Timeline

Start

2024-06-21

Primary completion

2029-06-21

Completion

2029-06-21

Drugs

Indications